Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A3 | Q9HAS3 | 2/20 | 0.37 |
| ▸ | F10 | P00742 | 3/20 | 0.35 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.34 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.34 |
| ▸ | F2 | P00734 | 2/20 | 0.34 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.34 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.34 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.34 |
| ▸ | F7 | P08709 | 1/20 | 0.34 |
| ▸ | F3 | P13726 | 1/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8271555 | 1.00 | SLC28A3 (0.37) | SLC28A3F10SLC5A1SLC5A2F2 | |
| SCHEMBL8271553 | 1.00 | SLC28A3 (0.37) | SLC28A3F10SLC5A1SLC5A2F2 | |
| SCHEMBL14269790 | 1.00 | SLC28A3 (0.37) | SLC28A3F10SLC5A1SLC5A2F2 | |
| SCHEMBL8271556 | 1.00 | SLC28A3 (0.37) | SLC28A3F10SLC5A1SLC5A2F2 | |
| SCHEMBL4870354 | 0.98 | SLC28A3 (0.35) | SLC28A3F10SLC5A1SLC5A2F2 | |
| SCHEMBL4877826 | 0.92 | SLC28A3 (0.35) | SLC28A3F10 | |
| SCHEMBL8084204 | 0.92 | SLC28A3 (0.37) | SLC28A3F10SLC5A1SLC5A2F2 | |
| SCHEMBL6778930 | 0.91 | TSHR (0.38) | F2 | |
| SCHEMBL19699426 | 0.91 | TSHR (0.38) | F2 | |
| SCHEMBL16436970 | 0.91 | TSHR (0.38) | F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051388-A1 | Novel Compounds That Inhibit Factor Xa Activity | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2008-02-28 | — | — | US | disclosed |
| EP-1773855-A1 | NOVEL COMPOUNDS THAT INHIBIT FACTOR XA ACTIVITY | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006008141-A1 | NOVEL COMPOUNDS THAT INHIBIT FACTOR XA ACTIVITY | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051388-A1 | Novel Compounds That Inhibit Factor Xa Activity | SERPINC1, TFPI, F11 | SLC28A3 2331/4885F10 8/4885SLC5A1 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.